Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model

Abstract

TREM2 is an Alzheimer's disease (AD) risk gene expressed in microglia. To study the role of Trem2 in a mouse model of β-amyloidosis, we compared PS2APP transgenic mice versus PS2APP mice lacking Trem2 (PS2APP;Trem2 ko ) at ages ranging from 4 to 22 months. Microgliosis was impaired in PS2APP;Trem2 ko mice, with Trem2 -deficient microglia showing compromised expression of proliferation/Wnt-related genes and marked accumulation of ApoE. Plaque abundance was elevated in PS2APP;Trem2 ko females at 6–7 months; but by 12 or 19–22 months of age, it was notably diminished in female and male PS2APP;Trem2 ko mice, respectively. Across all ages, plaque morphology was more diffuse in PS2APP;Trem2 ko brains, and the Aβ42:Aβ40 ratio was elevated. The amount of soluble, fibrillar Aβ oligomers also increased in PS2APP;Trem2 ko hippocampi. Associated with these changes, axonal dystrophy was exacerbated from 6 to 7 months onward in PS2APP;Trem2 ko mice, notwithstanding the reduced plaque load at later ages. PS2APP;Trem2 ko mice also exhibited more dendritic spine loss around plaque and more neurofilament light chain in CSF. Thus, aggravated neuritic dystrophy is a more consistent outcome of Trem2 deficiency than amyloid plaque load, suggesting that the microglial packing of Aβ into dense plaque is an important neuroprotective activity. SIGNIFICANCE STATEMENT Genetic studies indicate that TREM2 gene mutations confer increased Alzheimer's disease (AD) risk. We studied the effects of Trem2 deletion in the PS2APP mouse AD model, in which overproduction of Aβ peptide leads to amyloid plaque formation and associated neuritic dystrophy. Interestingly, neuritic dystrophies were intensified in the brains of Trem2 -deficient mice, despite these mice displaying reduced plaque accumulation at later ages (12–22 months). Microglial clustering around plaques was impaired, plaques were more diffuse, and the Aβ42:Aβ40 ratio and amount of soluble, fibrillar Aβ oligomers were elevated in Trem2 -deficient brains. These results suggest that the Trem2-dependent compaction of Aβ into dense plaques is a protective microglial activity, limiting the exposure of neurons to toxic Aβ species.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 98

1. 1.

   Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003 ) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582–590.

   Not in our library10.1046/j.1471-4159.2003.01879.x

2. 2.

   Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016 ) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56–66.

   Not in our library10.1016/j.neuron.2016.05.018

3. 3.
   TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy · 2017

   No notice
4. 4.

   Berger H, Wodarz A, Borchers A (2017 ) PTK7 faces the wnt in development and disease. Front Cell Dev Biol 5:31.

   Not in our library10.3389/fcell.2017.00031

5. 5.

   Boerboom D, White LD, Dalle S, Courty J, Richards JS (2006 ) Dominant-stable beta-catenin expression causes cell fate alterations and wnt signaling antagonist expression in a murine granulosa cell tumor model. Cancer Res 66:1964–1973.

   Not in our library10.1158/0008-5472.can-05-3493

6. 6.

   Bouchon A, Hernández-Munain C, Cella M, Colonna M (2001 ) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194:1111–1122.

   Not in our library10.1084/jem.194.8.1111

7. 7.

   Buchman JJ, Durak O, Tsai LH (2011 ) ASPM regulates wnt signaling pathway activity in the developing brain. Genes Dev 25:1909–1914.

   Not in our library10.1101/gad.16830211

8. 8.

   Busby V, Goossens S, Nowotny P, Hamilton G, Smemo S, Harold D, Turic D, Jehu L, Myers A, Womick M, Woo D, Compton D, Doil LM, Tacey KM, Lau KF, Al-Saraj S, Killick R, Pickering-Brown S, Moore P, Hollingworth P, et al (2004 ) Alpha-T-catenin is expressed in human brain and interacts with the wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med 5:133–146.

   Not in our library10.1385/nmm:5:2:133

9. 9.

   Campbell SK, Switzer RC, Martin TL (1987 ) Alzheimer's plaques and tangles: a controlled and enhanced silver staining method. Soc Neuroscience Abstr 13:678.

   Not in our library

10. 10.

    Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M (2003 ) Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 198:645–651.

    Not in our library10.1084/jem.20022220

11. 11.

    Condello C, Yuan P, Schain A, Grutzendler J (2015 ) Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun 6:6176.

    Not in our library10.1038/ncomms7176

12. 12.

    D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT (2003 ) In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol 62:137–145.

    Not in our library10.1093/jnen/62.2.137

13. 13.

    Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I (2018 ) Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173:1073–1081.

    Not in our library10.1016/j.cell.2018.05.003

14. 14.

    de Olmos JS, Beltramino CA, de Olmos de Lorenzo S (1994 ) Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicol Teratol 16:545–561.

    Not in our library10.1016/0892-0362(94)90033-7

15. 15.

    Devotta A, Hong CS, Saint-Jeannet JP (2018 ) Dkk2 promotes neural crest specification by activating Wnt/beta-catenin signaling in a GSK3beta independent manner. Elife 7:e34404.

    Not in our library10.7554/elife.34404

16. 16.

    Diep DB, Hoen N, Backman M, Machon O, Krauss S (2004 ) Characterisation of the wnt antagonists and their response to conditionally activated wnt signalling in the developing mouse forebrain. Brain Res Dev Brain Res 153:261–270.

    Not in our library10.1016/j.devbrainres.2004.09.008

17. 17.

    Diks SH, Bink RJ, van de Water S, Joore J, van Rooijen C, Verbeek FJ, den Hertog J, Peppelenbosch MP, Zivkovic D (2006 ) The novel gene asb11: a regulator of the size of the neural progenitor compartment. J Cell Biol 174:581–592.

    Not in our library10.1083/jcb.200601081

18. 18.

    Dunn KW, Kamocka MM, McDonald JH (2011 ) A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol 300:C723–C742.

    Not in our library10.1152/ajpcell.00462.2010

19. 19.

    Focke C, Blume T, Zott B, Shi Y, Deussing M, Peters F, Schmidt C, Kleinberger G, Lindner S, Gildehaus FJ, Beyer L, von Ungern-Sternberg B, Bartenstein P, Ozmen L, Baumann K, Dorostkar MM, Haass C, Adelsberger H, Herms J, Rominger A, et al (2019 ) Early and longitudinal microglial activation but not amyloid accumulation predicts cognitive outcome in PS2APP mice. J Nucl Med 60:548–554.

    Not in our library10.2967/jnumed.118.217703

20. 20.

    Fonseca MI, Zhou J, Botto M, Tenner AJ (2004 ) Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 24:6457–6465.

    Not in our library10.1523/jneurosci.0901-04.2004

21. 21.

    Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PC, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV (2018 ) Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. Cell Rep 22:832–847.

    Not in our library10.1016/j.celrep.2017.12.066

22. 22.

    Gage PJ, Qian M, Wu D, Rosenberg KI (2008 ) The canonical wnt signaling antagonist DKK2 is an essential effector of PITX2 function during normal eye development. Dev Biol 317:310–324.

    Not in our library10.1016/j.ydbio.2008.02.030

23. 23.

    Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM (2015 ) Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc Natl Acad Sci U S A 112:E3699–E3708.

    Not in our library10.1073/pnas.1510329112

24. 24.
    New insights into the role of TREM2 in Alzheimer’s disease · 2018

    No notice
25. 25.

    Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G, McGinty D, Anselmo A, Sadreyev RI, Hickman SE, El Khoury J, Colonna M, Tanzi RE (2019 ) TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer's disease. Neuron 103:820–835.e7.

    Not in our library10.1016/j.neuron.2019.06.010

26. 26.

    Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, et al (2013 ) TREM2 variants in Alzheimer's disease. N Engl J Med 368:117–127.

    Not in our library10.1056/nejmoa1211851

27. 27.

    Haass C, Selkoe DJ (2007 ) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112.

    Not in our library10.1038/nrm2101

28. 28.

    Hamelin L, Lagarde J, Dorothée G, Leroy C, Labit M, Comley RA, de Souza LC, Corne H, Dauphinot L, Bertoux M, Dubois B, Gervais P, Colliot O, Potier MC, Bottlaender M, Sarazin M (2016 ) Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain 139:1252–1264.

    Not in our library10.1093/brain/aww017

29. 29.

    Hansen DV, Hanson JE, Sheng M (2018 ) Microglia in Alzheimer's disease. J Cell Biol 217:459–472.

    Not in our library10.1083/jcb.201709069

30. 30.

    He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ, Yue C, Dengler C, Stieber A, Nitla M, Coulter DA, Abel T, Brunden KR, Trojanowski JQ, Lee VM (2018 ) Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29–38.

    Not in our library10.1038/nm.4443

31. 31.

    Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, et al (2015 ) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14:388–405.

    Not in our library10.1016/s1474-4422(15)70016-5

32. 32.

    Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B (2016 ) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352:712–716.

    Not in our library10.1126/science.aad8373

33. 33.

    Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J (1999 ) A new secreted protein that binds to wnt proteins and inhibits their activities. Nature 398:431–436.

    Not in our library10.1038/18899

34. 34.

    Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, Del Tredici K, Field H, Fulop T, Grassi C, Griffin WS, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, et al (2016 ) Microbes and Alzheimer's disease. J Alzheimers Dis 51:979–984.

    Not in our library10.3233/jad-160152

35. 35.

    Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, Weigand SD, Therneau TM, Knopman DS, Gunter JL, Jones DT, Graff-Radford J, Kantarci K, Roberts RO, Mielke MM, Machulda MM, Petersen RC (2018 ) Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141:1517–1528.

    Not in our library10.1093/brain/awy059

36. 36.

    Jacobs HI, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, Papp KV, Rentz DM, Sperling RA, Johnson KA (2018 ) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424–431.

    Not in our library10.1038/s41593-018-0070-z

37. 37.

    Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT (2015 ) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212:287–295.

    Not in our library10.1084/jem.20142322

38. 38.

    Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE (2017a ) Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci 37:637–647.

    Not in our library10.1523/jneurosci.2110-16.2016

39. 39.
    TREM2 in Neurodegenerative Diseases · 2017

    No notice
40. 40.

    Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, et al (2013 ) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368:107–116.

    Not in our library10.1056/nejmoa1211103

Cited by papers we hold 9

• A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models · 2023
  No notice
• Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials · 2023
  No notice
• Microglial VPS35 deficiency impairs Aβ phagocytosis and Aβ-induced disease-associated microglia, and enhances Aβ associated pathology · 2022
  Not checked
• Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer’s disease mouse models · 2022
  No notice
• TREM2 dependent and independent functions of microglia in Alzheimer’s disease · 2022
  No notice
• Exploring Sex-Related Differences in Microglia May Be a Game-Changer in Precision Medicine · 2022
  No notice
• Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function · 2021
  No notice
• Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions · 2020
  No notice
• Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.